Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2017.0259
EDITORIAL
|
Palbociclib a novel drug for Breast Cancer patients.
|
|
Affiliation: Department of Medical Oncology, Medical School, University of Ioannina, Stavros Niarchou Avenue, 45110 Greece.
E-mail: deziogas@gmail.com |
Abstract
In contrast to rapid progress for (HER2)-positive breast cancer with trastuzumab and trastuzumab-emtasine conjugate (T-DM1) agent no targeted drug has been developed for HER2 negative women with breast cancer, yet. Recently, Palbociclib has approved by the FDA for postmenopausal women with estrogen receptor – positive (ER+)/HER2-negative metastatic breast cancer. Future perspective and challenges for this subcategory of patients are discussed.
(Citation: Gastric & Breast Cancer 2017; 12(1): 7-12)
|
|
| You can have an online full-text access and a PDF of this article: |
- Either purchase this paper for €35 EUR. Please, click here
|
|
- Or through one year subscription PayPal
|
|
Online
ISSN : 1109 - 7647
Print ISSN : 1109 - 7655
 We
subscribe to the HONcode principles. Verify
here.
please, read our policy about privacy
and confidentiality of information and transparency
of sponsorship
last
update: 25 February 2017 |
|
